Conditional survival of trimodal therapy for nonmetastatic muscle‐invasive bladder cancer: A <scp>SEER</scp> database analysis

Abstract

Conditional survival rate of surviving to 5-year after TMT kept a relatively stable level over time. In addition, those adverse variables were not always the prognostic factors over time. Only age was always the significant prognostic factor for conditional OS from baseline to 5-year survival. Our results provided real-time survival information and prognosis estimates to adjust follow-up plans for nonmetastatic MIBC patients after TMT.